Syneos Health (SYNH) 29 Apr 222022 Q1 Earnings call transcript

00:08 Good morning and welcome to the Syneos Health First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. 00:23 I would like to hand the conference over to Ronnie Speight, Senior Vice President of Investor Relations. Please go ahead, sir.

everyone. morning, Good XX:XX the and are Michael on Meggs, Macdonald, Michelle Keefe, Brooks. call me Alistair today Jason With

disclaim In the addition our to expectations, of expectations corresponding Remarks constitute to regarding of the we them. growth, results press the provisions by release, we under prepared that pandemic purposes results is XXXX, a trends, remarks update the anticipated the forward-looking are available Form Act Safe Risk and section these call, and to accordance about certain Reform for Private COVID-XX obligation on statements Ukraine Litigation make website XX:XX in financial investor.syneoshealth.com. our at may future and war During and slide our presentation These from replacement Securities the financial to be statements GAAP. as differ a we for supplement non-GAAP a result forward-looking effects operations. XX-K measures, any measures prepared and our XX:XX those considered for Harbor of Actual materially indicated discuss of December factors in of measures core consider other which Factors transactions discussed to not various outside XX, our this our events with exclude year will These important ended should of the filings. be XXXX SEC in we the and non-GAAP a factors.

directly presentation. please to comparable over to For a XX:XX Alistair? the like measures, most now of financial Macdonald. reconciliation would turn GAAP the Alistair non-GAAP to with I the of refer measures appendix our call

us morning, for Good everyone you Ronnie. joining X:XX today. thank Thanks, and

the news some Health, President earnings moving Health with spending leading our years right current Board that having I'm today. was we the unanimous CEO job. decided and from results, for role Before search company. forwards. choice and worked Syneos I the we quarter Board extensive announced I'm since Commercial our the following our very Syneos begin and of be of wanted us the that assuming our by Michelle have proud retire Medical will is an with Keefe, to person of XXXX, XX:XX XX to she After alongside Solutions Affairs share I discussing important Member Michelle conducted that confident first process

succession the effective stepping Board today. I in plan as and now With member place, down the will CEO of be

However, continue months next I transition. an in advisor for order as ensure a will the few smooth to

we with integrated transforming XX into years Health have organization company, my progress contract firmly from incredible research new better and a made next During take biopharmaceutical for are value its ever to fully and market before. solutions with growth we provider. full for Syneos solutions chapter. XX:XX small, have traditional the a creation and a Today leader The confidence positioned long-term into right Board, the compelling time position established, that than integrated company the is our now I

a our into company has here the in building to our Health The an in leadership, brings execution, take necessary Michelle's Michelle Syneos as ongoing we continued year our senior management become unique double-digit commercial team, four services the like strong second by leadership of and to has and driven Syneos in world-class organization I'll she growth. member established the of today, some and customer XX has the know our momentum innovative as and launching has XXXX, as she life In drive Michelle experiencing development driven expertise such where next year a of the straight drive Syneos development us our industry, Commercial her track is she product development a future. first just era results, strengthened by comments. She insights of Health's commercial the and and commercial joins affairs, an back to integrated hand while XX:XX approach I it customers data sciences XX:XX is and her offering. business and alike. collaborating During into organization Solutions organization. before growth transformation product record full team Since success. employees and Under trusted quarter One include her years, turn service services the accomplished right diversified unique with the executive an innovation respected portfolio. its to across to leader the Michelle? continuum Kinetic career business, built impressive And over herself brief invaluable has medical successes joining our enhancing

for our care push priority to tremendous level next driven XX:XX market that providers. the thank built insight leader. care XX:XX passion the needs to his approach customer creating look through years to and and of top with our transition, To forward on newly and pleased brings past I and development, the clinical to role. growth, Operating from new clinical in XX:XX Michael work the disciplined distance investments current Global and end-to-end life. XX:XX that responsible lab to to been people on over connection provide together with I on company's our head want where to in we Michael technology Alistair my with customers Head does to next start, to take a strategic greater these of our experience is and Development this Alistair. driven focus excellent for And his that and Chief has we am position also our portfolio, affairs role seamlessly forward that as of his driven Syneos XX Syneos guidance and As towards of have and solutions from data to phase purpose this Officer. look insights intelligent to Development and solutions evolution will goals. a accelerate connecting us leader capabilities innovative to industry-leading years. vision share future. deliver I four customers He enterprise As this I of commercialization benefiting through be to the help our eager mentor He today for our success it medical than thanks created I the I development and sites As insights. impactful our more health into am Brooks, and opportunity stands Solutions it partnership an with half is I for ahead I COO, opportunities by Health to commercial a patients, appointed see Chief on and Health shorten integrated energized more and Officer will be and becoming building our solutions more will health technology a Clinical Thanks, get the role, conversation started. to an XX:XX tailored meaningful our customers

to Alistair on and to our to possible. update XX:XX Over customers, weeks. I'll on turn back the investors many to an to perspectives call. as you I look next and partners learning from I'll the quarter. forward hear coming all listening our our With earnings that, the providing employees, first be discuss business call as

forward. new guidance great metrics. growth pride I'm Michael the you quarter to our report XX:XX congratulations financial watching Syneos delivered and you both results. these Health profitability, exceeding Michelle that you, if pleased across take of to Thank of taking on Now organization all the with our and Syneos another within roles revenue Health. XX:XX turning strong to be and We'll midpoint

our integrated our advance compassion site and to in I acknowledge the discuss seamlessly the value success. the continue We accelerate organization to employees partners across region. proposition, gratitude our Ukraine war offer I in results, want to XX:XX to and Before working and care,

on safety importantly material employees impact our top our safety the the clinical both war has to have had and remains minimize we and in a on the Ukraine Thus the teams the our While of trials inside more and not serve. business. of far our outside Ukraine priority, maintain worked patients families tirelessly their impact

XX:XX impacted value Our thoughts who across remains with Demand pipelines been solutions business are war new commercialization robust development high with our from for healthy, and our has by through ongoing devastation. the everyone organization.

SMID all flow levels. strong and exceeds including strong year-to-date the pre-COVID above across to well where We XXXX are segments, demand see RFP continued sustained of levels customer customers

we impacts quarter. of previously plan. more Now the customers are opportunities key us our pandemic the XXXX, for seeing We with highlights for execute larger outlined on addition, we for XX:XX as strong creation This have In pharma preferred from awards sustained growth. the as continued remain provider growth growth subside. relationships positions some value confident in the we long-term backlog and

achieve XX:XX with performance, Deployment approach Commercial of compared commercial. Syneos impacts growth for Clinical book-to-bill XX.X% XXXX times Solutions for expenses, of and the beyond. in we company commercialization in increase reimbursable Solutions to and resonating full XXXX, XX.X% to Second, One Solutions for Commercial with for beginning milestones, first Total trailing commercial. solid our net the our an in continues grew strong business portfolio demonstrate the first customers ratios service XX.X% QX, X.XX resulting reimbursable X.XX remains reported for strong excluding our X.XX awards First, ratios times times quarter, the Clinical excluding of XX.X% end XX.X% a well-positioned of excluding in growth. With book-to-bill Commercial backlog Solutions the driven for revenue resulting expenses, to and clinical XX-month by of increase in for growth reimbursable at business and expenses, times X.XX and quarter

we revenue quarter. under growth on including Clinical both $XXX quarter, grew of our details own the driven In X.X% first the impact quarter in deployment, capital into acquisitions. balanced revenue of growth XX:XX XXXX, approach results. shares In first by of to year-over-year, worth compared to during delivered moving of the robust total Now Third, the first million further segments. our Solutions, our company repurchased we XX.X%

well relationships. balanced portfolio across in full strength service Our FSP customer and as our was SMID segment organic oncology our in as pharma ongoing continued ramp growth with our our portfolio business large the and

relationship and have related awards, includes existing material commercial relationship provider war pharma relationship. of working our Including local quarter, products the safety not strategy. growth example closely and our with product from serve. quarter marking highlighted. strong segment the our of expenses, hybrid revenue is revenue another our to with quarter reimbursable recently an our expanding with of the of continue As multiple and services in key Ukraine our with preferred new book-to-bill sanctions aiding times, clinical for a an is we growth therapeutic stabilization year-over-year returned book-to-bill and that patients included This growth. top mindset XX relationships partners employees ensure global building X.XX to customer the first This impact a development and on a top times. of another seen how teams will XX-month of results commercial momentum revenue areas clinical We was secure resulting to the across we XX:XX in coupled ratio customer first our previously and highlighted, milestone the clinical our Importantly, XX:XX Clinical the in we a trailing we are which X.XX and another XX delivered pharma important capabilities customers ratio

was ending quarter reimbursable was XX:XX to growth Excluding backlog first compared Revenue of expenses, the growth Solutions. to at year-over-year Turning strong Commercial our Clinical XX.X% Solutions XXXX. XX.X%.

continued rates our and remained driven in by in growth Commercial Our our broad-based segment. SMID customer Deployment consulting, growth highest with Solutions strength

portfolio related see another in to resources of We our launches to five-year revenue deployed in XX:XX also significant Deployment additions assets. Deployment contribution began Solutions One reached high new team since total with XXXX. growth quarter from highest Solutions the Syneos to the

regulatory reimbursable Our strong planning net communications our from quarter of Syneos very a remained end-to-end traction continuum our progress for in resonate offering times with customers X.XX additional continues and and public portfolio XX-month Our approvals. well One The with the book-to-bill relations in had X.XX solid new awards in also late The for XX:XX the ratio when activities for XXXX, medical including along appropriate basis, the to commercial product team of to the across market. trailing gain subject quarter commercial launches with quarter. times a and this unique launches businesses to expenses. continue

into our In awards, driven the addition business. Syneos has to the substantial growing clinical portfolio One

Lee new this Ken across recently XX:XX as and Clinical bring expect Asia-Pac in revenue expertise awards unmatched add our years. in this added to joined to who talent drive growth market. Vice offering and and Manager further management over coming important President Clinical expanding We both Executive of commercial unique We Commercial Development our Health Asia-Pacific, the Syneos for rapidly General senior region. in

life development growth lead we our the Suma XX:XX our our head Vice business, Medical Senior commercial commercial focusing our go-to-market across welcome on the model expand tools and of further Solutions data optimization Wilson, medical Sam in and strategy. will solutions Lastly, design also We drive across of we Deployment President to Head Shetty to as representing at investments seamlessly promotions dynamic will announced network. the delivery new both Ramadas new connecting strategies. and facing value the Baba core across Executive cycle. of XX:XX the and Technology of region, the Suma solutions, key Asia-Pac to continue growth comprehensive in and of and integrated Data recently to high digital solutions driving including assembly Baba customer as President affair advanced AI-based product development President, the Affairs, technologies enterprise organization's our capabilities the Vice Solutions roles

their initiatives. is retain growth some our years XX Our Health. at highlight employees We performance achieve (ph) Syneos and attract, support testament the important about dedication Jason, to successfully to I ahead in to climate and ability their Paris of tirelessly culture provide to optimistic colleagues our of XXX our for net economy. more will look additional opportunities demonstrates to they agreement. financial with provide remain and before We financial forward low-carbon on delivering to XX:XX ESG commitment a comments and plus patients, talent seamlessly the behalf formalizing executing for we recently I career on by other delivery. On Jason? zero shift XX,XXX of closing, the goals. to XX:XX emissions ahead on customers Syneos wanted all organizations to year our In guidance. exceptional joined XX:XX I work innovative continue stakeholders, hand to pledge, it our collaboration level an Health as pledge to over want the and our of my other climate the carbon for top projects proudly XXXX, while now growth our and and solutions the promote than Finally, and update Jason signed and thank a

and morning, everyone. XX:XX Thank you, Alistair good

work say I to that Before the a Alastair with the into I past details, over been get want years. to it's eight pleasure

to as Business XXX on than XX-year some $XX revenue the company an Associate when the He Director company of of in Just and XXXX employees. at provide company. less perspective Alistair's projects joined the had million

for employees and achieved $X.X We and of me, the last billion you've are over of efforts the recently to company led strong the done XX the just XXXX. years our now the our especially through DE&I couple and in XX,XXX quarter pandemic, revenue employee company first all as the XX:XX years, continuing in over Thank for war. you've of the ESG most Russia-Ukraine ramp COVID-XX and last you

will missed. You be

in Michelle future, the closely the of company continuing in to December As COO. the Michelle we working with CFO joined years. since. I've roles forward XX:XX XX:XX over together I work was I'm When with her both opportunity their in look four the to CEO to to last and and half the Michelle ever had work segment. as Commercial to quarter. Michael looking And new and closely the been we've Turning XXXX, Solutions

Revenue XXXX. revenue quarter to in for total XXXX business in up despite compared foreign XX.X% strength our expectations increasing the first from was $X.XX the above clinical currency came of first of XX.X% to Our constant exchange. an due quarter and headwind billion, our the in

basis for from partially the payment pharma customers quarter Clinical for of increased expenses, adjusted XX:XX revenue an increase days, XX.X%, the Operating Adjusted reported, favorable consistent and of compared segment $X.XX the Solutions Solutions, facing segment. have service EBITDA our material ramp contribution in portfolio margin first for Syneos noted a XX.X increase headwind an includes flow the portfolios, executive the customer was total solutions minor compared contribution and particular balanced updated growth, of This was earnings point for growth the X.X% $X.XX receivable was the XX expectations Solutions full basis large to did our in by from experienced primarily lower field to with increased our of our and XX.X% growth XXXX. first reflect an to diluted XX:XX of impact currency expenses consolidation first and launches increase reimbursable adjusted revenue revenue was benefits DSO XX:XX assets. mix. growing quarter EBITDA adjusted or be an primarily XXX million, $XX.X EPS and Our XXXX. of interest reimbursable our Adjusted and a expansion oncology a to mostly exchange not constant was by within driven that Our margin foreign currency compared the quarter strength up growth under up of continued by revenue in quarter with quarter XX.X% Growth recast growth. we X.X% EBITDA to in in These driven XXX guidance. related as of to Commercial in the businesses, in at a first point representing team strength billion, of reflect million Deployment a the data $XXX.X cash including first were quarter Commercial or revenue result and including expenses, first the on first XXXX. terms. our FSP with expense. our in technologies reflected our driven across XX%, the commercial increase increased XX.X% today to One Clinical by leadership presentation, for Solutions million, of constant in accounts in business core As longer $XXX.X offset basis year-over-year, driven from relationships. increases comments revenue by points our large to pharma acquisitions, Reimbursable The XX:XX first quarter in quarter our commercial less in EBITDA

$XX.X quarter. Our the capital first for expenditures were million

these We of first ended million revolving resulting facility. a million and During net repurchased in our our times. shares. outstanding cash total quarter, $XXX on X.X and funded repurchases quarter $XXX unrestricted with the hand credit debt we billion, outstanding We on the borrowings of $X.XX cash of of short-term leverage with

was to XX.X%, for view This XXXX. the for COVID-XX related Turning non-GAAP our on the quarter guidance. the environment. war year updated XXXX evolving our and Russian effective business sanctions pandemic, the now guidance estimate our rate contemplates the Our tax consistent of with the XX:XX of impacts interest rate estimated and of full the Ukraine current in our

In addition, of foreign this exchange on March guidance XXXX. is as based XX, rates

expected first or at share the interest range was $X expense. This diluted benefit offset $X.XX an growth XXX for expect to repurchases, margin to EBITDA of revenue to approximately basis in we now $X.XX adjusted net growth million from million of $X.XX total million, Our of to from from includes million. midpoint, XX.X% by adjusted range reflects our up $X.XX increase expect to XX.X% headwind basis XX.X%, from points EBITDA XXX $XX This XX.X% at reimbursable a estimated exchange XXXX. acquisitions increase contribution XX:XX $XXX billion at which approximately increased quarter of X.X% an our representing representing an points expectations Total billion, EPS of $X.X an revenue and of despite XX:XX Lastly, XX basis increase of growth of remain foreign the total to of headwind We reflects XX.X%. midpoint. unchanged our to adjusted points the to an an year-over-year $XXX expenses. from now

reflects million. count for range market also XXXX Guidance non-GAAP incorporates to based is range and shares. This $XX now effective expect XX% a cash income rate. of debt XX.X% of interest million for our of during from estimated $XX of upon share our guidance Further, to tax is million current outlay forecast taxes million. $XX rate and diluted million an we net $XX expense that to $XXX.X Our variable LIBOR assumes XX:XX

acquisitions due total any expect million. exchange to billion reflects, to foreign a $XXX quarter of to from XX.X% XXX contribution prepared as to approximately revenue completes of reimbursable and estimated growth to basis our and Operator? adjusted reported points, a XX.X% We of million answer we EBITDA of X.X% remarks, questions. and an growth expenses. points EBITDA $X.XX of $XX includes This XX:XX the XXXX. and will headwind $XXX growth $X.X happy of adjusted headwind approximately XXX second of compared revenue basis be quarter second revenue to This of million billion This to X.X%

XX:XX Our line question the [Operator from Instructions] Patrick of from first Citi. comes Donnelly

Your is line now open.

I on talk what be Lizzie and This outlook (ph) view for of Patrick. hear would you if could to Hi, both deals M&A is XX:XX was just on the great you. guys. wondering, there environment current from just Thanks. for your is about your

while we mean, got at and the XX:XX look with that actually we cetera. across out priorities now, things had deployment of things forward Sure. a Good the et business we in. of we kind affairs we've both Commercial, looking But of for we the terms Synteract environment moment and we've I into that want morning. priorities in little Clinical bit medical the continue good that move business, capitalize kind like -- did of M&A, tuck-ins, the Yeah. a is targets help think place selling at as StudyKIK a and RxDataScience and have is and a to engagement I off or capital cooled list that base us

thoughts digital continuing engagement for bring your So systems. of Michelle, mean, that. to processes I and look and of also digitization on kind things that

the business us business the about we're along. things really excited come organization more the as good tuck-ins good existing very about acquisitions and Yeah. a become We're our XX:XX really they running is data-driven performance we're Well, approach. what right helping seen integrated opportunities there and that there are for much But way solutions our we pleased now. with Hi. assessing are we've out the to build -- really just some feel is, of

Yeah. XX:XX

I’m it And all XX:XX Thank guide, the conservatism just the on in of thanks then giving any questions. does strong, XQ that taking And one the year? for at pretty you. a assume more half my Great. back

Jason, XX:XX that? want to answer you

XX:XX Yeah.

it we've where at half, to in ability as the the to year good situations we allows balance is really the these some the work the sort the of looked themselves have was. So, world back early and guide it And just as your the QX back some in out we felt half point for about of macro let of that out.

So I we wouldn't we've be say conservatism, or And it's the want it to where I help would across to growth us or whether everything might take we technology periods. want data and whatever in say in drive previously, to it, also company, talked balance. investments the people look future its that at about

you. Thank XX:XX

line comes Baird. Eric Our the from of from next Coldwell question

Your line is now open.

Alistair, Thanks Hey. congratulate and promotions. you very let first Michael Michelle much. be on the to on me the XX:XX retirement, and the

Thanks, Eric. XX:XX

Commercial. want on I hit Thanks. XX:XX to

growth. if Syneos curious of hands, disruptions. product love on this recently deployment digital, market and are back market to to causes love changing the some comments years the of on maturation growth the example, this remote dynamics and sounds into balance sound levels the work competitors backlog new Is good about One, or returning to, XX:XX if competitive you've versus market, existing largest have going the recovery good just today, curious between on the Thanks the that how sometimes your had of wins, much. I'd more landscape pipeline. live you in is returning normal I'm is there enthusiasm First, momentum in And good wins or clients like recent meetings. then, it work the is I'm regular Second, to broad way it you [indiscernible] two just the growth is in launches rates, competitive this for to Michelle, positive very COVID, very this landscape, changes the get or on virtual, finally, but get the about one I'd the is with backlog update

the XX:XX of Well, with, start first, thanks the really for been team I'll questions, Eric. the has impressive. Commercial performance

X.XX has of the beat X. book-to-bill to between want XX-month what on, focus X.XX trailing we kind and given area is we've of Our which really

fact point, So on XX%. backlog hybrid digital really mean a has Deployment been we to Deployment think this over to And some are to the we is multiple with just to of of center where I to our think solution create manage great that Solutions used street, growth and your can COVID the real Solutions with channels I the really feet enabled and call lot times see people success representatives communicate momentum. has capabilities continue video customers.

our in-person we're I and this differentiation really enabled sure, We fact area, are the visits why driving seeing been with a growth that varies for in ourselves rebound differentiating having. that impressed truly obviously believe success. solutions it's is that really the hybrid the we market, by have therapeutic but are our tech is which having we're

the Commercial that answer first So I'll with question take would question. Syneos think the I One. XX:XX second to the be

second We're second As you half which very are the It's half why of them of and know, the growth good have great about we of many starts the ramp Idorsia really in that portfolio have year, a clinical. assets, is ramp. it's of this in still in the to year. excited a we really

how portfolio clinical continues grow. I to to perspective. the little And forward over We talk saw And One teams does well. were will early we Canada awarded, XX:XX turn it business Idorsia to to looking Michael from consulting get seeing we're side. Syneos on business bit clinical in press communications a awarded European a our as release, for with our the about early, also you it and in the the were and

Michael? So,

Sure. XX:XX Yeah.

the from the with development operating product model with [indiscernible]. at operating group, approach of is looking clients. very like our just how we the mindset, Clinical how we're of idea yeah, One So the the They lens resonating Syneos the well leading

as the patient we're clients solutions Just forward practical. with insights importantly bringing through they're resonating because that also integrated data tech is

we how come really talent value of the they been really from You real customer, and In seeing patients target landscape the or design to that of competitors We've and the other year, increase XX:XX our what protocols, changes an delivery differentiators, biotech helping or then quality. come our how this customer, have we model, us in how and customers about bringing we've and And And perhaps exceptional talent the how through. they operating finally, customer, backdrop one been And exceptional in in are think I our that's can geographic on also other customer, of some who've it's also with terms our recruitment. advantage relationships think CROs, [indiscernible], for for see that brought focusing great us. pipeline. the some with against pharma here. good simplifying

XX:XX middle. I Maybe the questions. miss did in So, Eric, of your one one

-- equity. in XX:XX I'm and competitive least the especially But Yeah. important. probably that recently about curious the to you've the large -- peers, I'm any one landscape of the changes seen if just private Not changed hands behavior your

kind XX:XX of in any take that, don't behavior. think I'll Eric. change I we've seen

to a funding penetrating this start clinical tail we we've that that I'm something the proud So I what Michelle of culture I team projects the super are up the resonates over believe here. is work to that really different. as SMIDs engage I built, as in that's to the well seeing have execution, we've asked together, projects. think our And large way, on know be you resonating or take people towards excited to forward. capabilities to the and service bringing that who year. the we significant relationship for horsepower And us capabilities, the about as we tail wrap kind any to a they truly cross-sell year, this real that continue And from their the the the think the landscape. Syneos that mean ramping want fact it's very their the towards on We whatever we more Not of some win in come legacy side way ramp different and One I going large thermo obviously built up scale really plus are what really pharma. it XX:XX we And kind we're journey to built of here of the want customers obviously about we great that. talked of seen I Michelle and skills the And holistically, to that and push and full good to with that's towards they're that. of And that advisory very them in go, pipes, in with a questions I good commercial a opportunities across, mean we big of is And supports would. serve. changes them compete as new pharma all ability catalog

we've I think, package it all put very a good very in situation. good a in

in company healthy and So direction. heading right the healthy market,

whether and intersect make affairs because success. the market competitors now strategy holistically just think I'll commercial Eric, and Yeah. our far. med seeing with with market value one with strategy sure talent commercial resonating being customers. it regardless is competitor it's or really that the proposition we in is I to full Syneos right is we about customer moved of And I specifically thing. beautifully by in leader the XX:XX add our their is compete the strategy. integrated where gets seeing trying private. a the commercialization, one regards we're have other Health they what to about what are earlier the are thinks like In they we're value What product think winning And to they're proposition, that thinking with we And us

Great. Okay. good Congrats Thank update. much. on very XX:XX you

XX:XX Thanks, Eric.

XX:XX you. Thank

the from comes from Morgan. of question Casey next line JP Woodring Our

Your now is open. line

Michelle, guys. for questions. guess congratulations Thanks off my welcome. Hi, and taking Alistair I first XX:XX

Thank you. XX:XX

the little I about strong talk stand a you or guess to capital market on where anything delays, in given out of RFP or talked Can year the Synteract market bit anywhere of else maybe cap SMID customer terms segment. just cancellations about SMID the environment. flow segment in So call for rest for maybe you And business now. outlook the the yeah, XX:XX your the

Yeah. Sure. much appreciated. Casey. Thanks, your Thanks XX:XX for comments,

said as we call, earnings I look at the when exercise SMID talked SMID cetera., the So environment like sector. a we that we et multi-channel funding last really think, and about

part what into still get work a obviously funding through got the goes It's see coming pretty the events, strong. have biotech. And of tracked index, that feed the good biotech in public through We So that it’s that et the in forms -- we Synteract with funding that secondaries cetera. IPOs, customers. we've along, that, model that also emerging there's moving engagement

that because keen cetera. we're to And money Syneos funding equity for our hundreds relationships we look end-to-end out dollar, it, their et cetera., to through wrapped on customers very the office, fact the big a on the One since we spending outsourcing the of and space. pushing very model I and that the One know great big houses it's ability those is work they think coming at model forward, around of it's biotech every in Again, -- take not the are a with go hiring now Asia. Syneos the putting private But then, to part biotechs, the molecule have them. different not to building able the with of work biotech is they an et they're do XX:XX people end-to-end SMID model

both so work through. those new in a set in and primarily terms delivering we coming record capable of think us for we're sales, healthy. world. the QX the in combined Asia of very SMID the And that channels And rest in obviously Asia I are But

the had where catch-up been against with which think showing COVID in equivalent lot past, look good of XXXX, when where we've at it that. back a the I to growth even we they're seems pipelines

the fact that, breaking healthy that and to to pharma, we're they that. getting anchor Add not relationships, adding us. in to the we're tenants by more picture through large very a backlog it's for more So that are new concerned

We're fine, the environment customers. funding with an not good at all. engagement issue So seeing as that

you around pharma Can pharma it. momentum side year-over-year And returning your Thank top talk business how in you preferred one. talked customer quarter, pharma here Got these provider growth with toward customer the you. you're XX:XX the winning segment guys about large that global That's specifically XX large and specifically? helpful. in then, on the

Yeah, off. absolutely. it kick XX:XX I'll

the side One scale we've scale day in and the that, like it we've out was transactions done be of the of on and it to back create points Syneos the the side. we've done commercial merger, in that of and on clinical competitive the done creating

commercial. are We biggest the in

I are we combine able getting the top feedback the a hybrids bringing three and our when as culture in about very we with that well clinical et we in compelling to We Michelle we're around that building in The as capabilities on side, the skills, well, abilities want advisory I'll pharma, affairs, new those in come awards have Michelle, team really little to the is that your in about got it. Clinical. bit well think from we're get talk deliver people large commercial, the excelled thoughts but and able medical have, that that deliver I have as engagement. where Michelle's we've that now a and cetera., to seeing being delivered are to think clinically us cross-sell very

opportunities they the way business offer real, deliver perspective of an why units this offering The in pharma in a win one top to kind together our expertise the a differentiated And the top a fit exceptional really XX:XX talents, clients. clinical. of exciting between an true company. and to in an we're commercial, largest integrated quarter clinical, been our some think Yeah. different with about to XX wins getting which XX the working in sure. this integrated best had We really we customers. regardless expertise of commercial these from And to It's goes of work sat a that together was for

pharma our had of side XX top -- commercial excited clients on win a clinical has because top door opened other the another just in as can well about it's so win. happen of And clinical us and as QX the tell biggest I we've had you really the we're one from for ten commercial that we've it well, clients. big one our

So we are with is the these and the way there responding integration between to them customers really businesses innovative, integrated solutions. the approach

I'll off chance Michael then So to a it we and can top give go.

XX:XX Yeah.

key points, two Just Casey.

about I it better how what restructure leverage far talking actually is to partnerships, about us can might operating can relationships be. existing really fulfillment, they're love they how our our existing now, just with not the models. whatever the First right they contract their solution, and How order

it's so, being around more transactional. integrated and And much solutions

are addition, need problems not the the irons clinical help few we In they solve. work, other We're have talking clients What solutions, existing in companies we've to pharma fire. us around may got them with where a quite to capabilities.

and the what with pleased the momentum also holds really future for we're us. So

XX:XX Thank you.

Christine Rains, Our Blair. of from next question the comes line William

open. Your line now is

congratulations, Michelle on position. XX:XX and new Hi. Congratulations on quarter the the

me. -- from The two Just yeah, awesome.

the Thanks. update any announcement, there you're to one The is if staffing that as or retention hiring may a if changes there's first other experiencing execution is relates on, given And in CEO on one come. vision is and discuss this any difficulties it fronts. can the you then new strategic

marketplace of -- for some value stabilize, it People seen at start I'll very from doing turn what couple a both stabilization the we're things and that think are staffing. about a But reasons. Syneos with out I second really we're it We've Health. have really I I that of seen doing staffing think XX:XX And some across is excited offering for innovative a and the questions, I'll Sure. talk we proposition things competitive Thanks innovative a and culture mean board. there retention to a Christine. right what to a on we're about talent Michael is is the it here perspective. really acquisition now.

poised era have how winning strategy. provider, as and focused analytics been and that driven targeting on how we've we and Kinetic. we've on do better insights next a XX:XX and really to support intelligence StudyKIK we data the enter thing. really [Technical through we this insights believe strategy, anything I really I would focusing we decentralization So can Difficulty] new through a think regards first And obviously to be are In

what going that over excited strategy enhanced partner the that enhancements It strategy about customers customers the -- have. what I'm every with we through we around, think transformations But time we're based as obviously Michael choice. re-imagining question about their has their has need. they're help and can really to the said be them to of last really models on goes trying in back help So that they

So a back I'll go to to about the staffing. Michael bit over turn to it little

Absolutely. XX:XX Yes.

our seems that even are opportunities, traditional the of that in role, the my every working one So prior group, commercial stabilized career I tight while said talent how We from excited labor the of that around single data where the be has about also projects our our retention on. we We're here see have pressure. pockets to we Michelle geographical and has of partners families, lens clinical specific resonating strategy or they're really our watch training of choices been market. it's be And can have pleased therapeutic feature development, some it that employees. as really Taylor is of group. at in was support to and really continues CRO we unique day, acquisition, new with the there to whether them is, XX:XX the within going to those terms the the giving it's very a action of innovation are taking those individuals and In that either couple whether a exist Syneos

them. on to So of exceptional we leaning do attractive help resonating Christine, ideas a with our how (ph) support really recruit how to talent, do compensation create new been do then we've top to line them, bringing a job also good things variety in as Obviously professional we infrastructure with make And provide development opportunity for seems those of invested onboard we've monitoring very employees. other we that career opportunity, group benefits. experience how employees. to really be that we a that management, and that's

Good. Pretty XX:XX

Next question.

XX:XX Thank you.

the Deutsche Bank. Our from Justin of line question comes from Bowers next

line open. now is Your

happy and morning, Hi. everyone Michelle. to retirement XX:XX congratulations, and Good Alistair

you. Thank Thanks. XX:XX

you. Thank XX:XX

strategic opportunities kind renewal And really It's cycle, the win opportunities mentioned. that cetera., of that et partnership on the One these you are positive Are commercial, typical cetera. just of outside for little was elaborate XX:XX things you, that can hoping call bucket. comments is I the the and top on in that dig a new deeper then could you et clinical, part there. of on landscape Yeah. XX the we

a trying better get to sense of the there. Just landscape

Yeah. XX:XX

opportunity, partnership. strategic yes, XX is So new this top a

one in have of original So renewing it waiting middle had And sometime is the It's in that. have for. been -- right COVID. about would very cycle that excited the this actually we

where in but a been to overdue, knew ourselves both side were it’s we the bit -- for working how We've the it's and customer past, clinical assets a bit -- on they I well think little position commercially knew So against done that. clinically that on. how that we work in little great we acquired already

really And work, service to to into And Partners of COVID, obviously. was compelling that front when So that are were which in kind took [indiscernible] large bridge which well them FSP then help as quite that Syneos the it delayed we landscape, think think. who kind to of approach Taylor normal one Strategy full innovative start an as find in little cycle our pushed very of was we for people of hybrid is to large to year. from we by come us the on offering. of power over with think is parlay I working in by Commercial renewals, a I to kind find roles very areas get out which bit, staff XX:XX I a them Clinical, and through later that to understandable will a customers,

So...

Absolutely. XX:XX

lot So we've this quarter. had of a success

a customers in and to up customers, So commercial we about, XX also on And clinical first side commercial as our see Clinical and see won. now getting we've to well. have business we've ready the big some too. starting are winning side that talked some on we've of us opened opposite RFP some others was to We're from side. had win are partnerships out the But the the seen reaching on top competitors side, we really have the been commercial flow on to one, we're win which starting the exciting. had that were Alistair commercial

have Michael the really been enjoy to responding cylinders customers SMID, about are able and to happen pieces this side, other like starting exciting year working we've enable see proposition. while very integrated And roll when pharma, to it's that and XX, so I to XX really on but kind on this together, to closely all more value we is top just that the a you you hitting for us. really And fact get journey have integrated in intelligent appropriately, it we're a so, a this think been you last And enterprise. it down which the uphill of the over top be I the not the in on put for value our to then proposition rock push watching think are

know want anything, So, you Michael. I add to don't if

as labor the the customers, want nuance as between with This and client much that of want pharma, fits the can, market top fantastic obviously employees to to had just this we to One grow. cultural fantastic win together. XX:XX culture leadership. And matters that particular And mix we we business a XX on employees our this work our want customer. in current

may the in we'll to with resonated authenticity it have I their sat So have are what we them, originally the them. problem with to give do future. you is wasn't We transparent committed And we can trying message, And about authentic What together? leaders. you're the and that solve? sales and with started talking talked we we to about down and solutions I a really think bringing what what today them to Alistair, build Michelle

of a us great relationships just into will candor, to success. don't great sales both strong They to And solutions, it's well I just ideas, and want going sales foundation relationship. where, other candor. to parties customer translate have and they So give a some that and fit authenticity honesty cultural we think as want

the think not It quarter. -- the the the IPO. like much sounds at since the follow-up the IMC stock tight buying -- in the talk maybe one maybe all back capital did One multiple stock Appreciate as just job M&A is for about good a has, Jason. guys original pretty detail. deployment you is philosophy we market it Can quick trading lowest I here, XX:XX from

are you about guys the that the rest thinking of how year? through Just

to are still in we'll year and our space on, of it terms Justin. hasn't to, just and the Yeah. we changed RSUs get plan. to the to creates three that have we options flexibility Hey, prevent that used do It we XX:XX -- majority will of, it things the in work our sort $XXX the and end we really dilution fairly here enough going minimum remaining want us at the we year, a of million then and in within the macro we're around on delever But of that $XXX that. had to where by Sure. it something for We want leverage shares. that with and from spots is pipeline tuck-in that repurchasing do continues alluded change and as the the just X.X typically as of robust Besides event last we what's coming in finally, Alistair was, we market and at when year out And M&A we the were that through, and environment. later. given and of every million opportunistic where will picking times vesting. And and on be

rest in the the we those 'XX. So move key through three as focus areas remain of

Thank XX:XX you. in Got it. I'll hop back queue.

XX:XX Thank you.

Our next Jefferies. the question from David comes Windley from of line

now line is open. Your

enhancement that the you capture And about the between Michele if XX:XX and congratulations taking Clinical we going them? to in kind from orchestrate pioneered. that talked a of full and launch questions. a of you've that of on Michael commercial from talk because And margin the kind a and you roles. best wanted for Alistair, control opportunities this are strategic questions. Michelle broader giving cross the Is relationships individually a base a then at that lot think you've career, about, your Commercial, new and side of of when more come kind a Hi. levers more luck these of successful my of could expand service services. on margin angle. Thanks you sold solutions, kind Thanks long those opportunity I to call margin for also to I taking you've on specifically guess, I as sale

Dave. I'll Well, start, well. your enjoyed you really long for with engagement Okay. XX:XX comments. We've as Thanks a

scale. terms to Yeah, relationship looking of been next this it's and forward really the we'd kind see pleasure, you it's of So, something its that's the to of relationship. -- you right the level. that when higher services, you but bigger it's with make a pharma Michelle margin, in take where kind business proposals SMID Michael be put the margin, relationships in The get of strategic where utilization -- and at it and expect a out full to much large together, for new with

So they This a other hybrid. kind each is they of blend out.

So it. it's both very I have and mean with, I and of going to to excited a bit think build upon we're engage

assets that. about Clinical this of their So like be -- Clinical from not we're We'll work and One excited across work now Commercial their style, taking a be very Commercial. we're big doing It's cross-sell. relationship and stretches part right but it's big something a big will Syneos a that part to of not a across

capable So that's think if carry differentiator I we key -- that style that Jason? more and I of And winning. come a Syneos forward. I that only think relationship think to of is the can

it different add And full-service of depends, think cross-sell then I With to right. services -- then what commercial Dave, to the commercial depends as commercial. moment, commercial, and it monitoring now just in commercial. guess, plus It doesn't on full-service XX:XX simple within full-service I risk, and the wouldn't it are et risk FSP the on cost as full-service at utilization margin profile cetera., that utilization

yes, around full full margin. consulting, better be teams, far those have to you going it's communications, field field full If a operations the and teams

the you margin profile If lower be of go a prior. little pieces to is of field going and those one little the pull a team, bit with bit just consulting, than and out a

full great say services really within in that. that If again to clinical depends going the into the it's standard the going. service you're cross-sell, team. business, want the which to it's services side On So the from cross-selling it depends then What I on would a Clinical XX:XX think on just we margins. on commercial into it's way it margin of underlying you just about cross-sell the terms be the if standard a see field field in team, from

XX:XX Yeah.

in just of kind it. depends So on what's

Yes. XX:XX

and XX:XX tend built you've Syneos that In Michelle, to you mentioned it's the One about there. -- ask the ramp focusing on, Idorsia there. I I pipeline specifically, think and

timing wouldn't you you if of itself. more elaborate mentioned those. A there, part in line-up ramp how expansion launch of the of stack the launches, and just does it, is up geographic Idorsia the the it the terms would it be, to And of what raw mind is So the is then on or product really the since driver

two XX:XX in answer So I'll ways. that

is full the XXXX U.S. launch, right. So half it the back the but -- is both, of

partner. the Idorsia put that that they saw press out us You release their chose as

with Aniston. Jennifer [indiscernible] XX:XX

And could you see Aniston. with the XX:XX ad Jennifer

XX:XX [Multiple Speakers] opportunity. [indiscernible]

Okay. XX:XX

full U.S. the launch is now. be, right So to going occurring

QX, So, a we'll up and have the It QX full breadth and QX. QX of in the U.S. right. launch ramp occurring in was

of in we'll obviously see you this and fully the U.S. hold launch year taking why that that's half back So continue.

the approved The country, they beyond, time. are from the happen, XXXX Canada on and right, in those obviously comes we across still resources happen into And approvals, us And to country EU. Idorsia in by the asking those will absolutely of second countries. right. EU was not that approvals announcement with and take regulatory will over the layer And additional as all

they've more partner. wide disease, as are at the know, something oncology assets, the very some rare all has an portfolio some it's physicians specifically, know insomnia When Idorsia because targeted we and portfolio, full commercialization, insomnia are disease. you versus base rare large Syneos side $X which publicly of as Syneos that's Health value you XX:XX So like that target know, their as you smaller asset look named on One and larger larger a Idorsia's absolutely

as So and And are we to which early that, they on, the win happens then, continue One yes, through Syneos deploying assets first through, comms, approved. we then get over resources and time. obviously that business, come obviously consulting whether it's hoping that

about of them But to make we not assets. might value some going know as them it those so, you the of are And know, potential license all full assets. talked we've or of their

business. fair think should share of So our defined that well that very we just -- but we get pipeline it's a really

so that you Thanks XX:XX and But for again. congrats. I'll congrats queue. back Thank very Yes, into it I've much. questions, asked does. long the

welcome. You're XX:XX you. Thank

XX:XX Thank you.

line Our next question of comes Securities. from the Sandy Guggenheim from Draper

now is line Your open.

to XX:XX Thanks. I it's at just looking am and with and but forward forward. say you Michelle to to not you going to been ask great the Alistair, congratulations wanted working question, going congratulations, working

that's over the it for it So I'll turn to me. people.

Thank XX:XX you.

that Appreciate XX:XX Thanks, Sandy.

over Ronnie back Thank remarks. like turn this XX:XX further I'm questions. would you. to to no At call for Speight showing I the closing time,

Okay. to Well, [indiscernible]. and Macdonald. XX:XX Thank I’ll turn hop I'll over it Alistair you, in

in sincere all neighboring -- I team confident in Well, to XX:XX Health my through. creation Ukraine achieved. years Ronnie. to capable beyond in now as a incredibly market in on profitability success and look XX:XX to the your watching forward I growth team great our our this CEO move remain as Syneos in I execute our forward for and all while particularly value And We of to wanted sign positioning offer to look Syneos customers the hands. most company continued Serving XXXX countries. the folks serve do strong entire proud our stuff we off, Thanks, the the sites in the the they I'll has to and thanks continue before and patients, as plan. I'm has been honor, Health to come

attendance today company. a So thank our you be Have investment great for in and and for continued safe. be everybody interest Please and good. your day your

today's concludes Thanks This participating. conference XX:XX call. for

disconnect. now You may